의료기기 검정 및 검증 시장 : 서비스별, 기기 클래스별, 기기 유형별, 용도별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Medical Device Validation & Verification Market is projected to grow by USD 2.34 billion at a CAGR of 8.72% by 2032.

Medical device validation and verification (V&V) has become a board-level priority as manufacturers face tighter regulatory expectations, more software-driven products, and higher scrutiny of clinical performance, cybersecurity, usability, and postmarket risk controls. In this market, V&V is not a final-stage checklist; it is an evidence strategy that connects design inputs, risk management, biocompatibility, electrical safety, software lifecycle controls, human factors engineering, manufacturing validation, and real-world performance monitoring.

The strongest medical device companies are building V&V programs around globally recognized requirements, including ISO 13485 for quality management, ISO 14971 for risk management, IEC 62304 for medical device software, IEC 62366-1 for usability engineering, IEC 60601 for electrical safety, ISO 10993 for biological evaluation, and applicable FDA, EU MDR, IVDR, Health Canada, PMDA, NMPA, and TGA expectations. This shift is increasing demand for traceable test protocols, statistically justified sampling, digital validation platforms, and independent verification partners that can support faster, audit-ready submissions without compromising patient safety.

Transformative Shifts in the V&V Landscape

The medical device V&V landscape is being reshaped by three structural forces: regulatory convergence, software intensity, and lifecycle accountability. The U.S. FDA Quality Management System Regulation (QMSR), which aligns more closely with ISO 13485 and becomes effective in 2026, is reinforcing global expectations for risk-based quality systems. In parallel, EU MDR and IVDR have raised the evidence threshold for clinical evaluation, performance evaluation, postmarket surveillance, and technical documentation.

Manufacturers are also validating more connected, interoperable, and AI-enabled devices. This requires V&V teams to test beyond traditional mechanical and electrical performance, adding cybersecurity verification, cloud connectivity validation, data integrity checks, algorithm performance monitoring, and human-machine interaction assessments. As a result, leading organizations are moving from document-heavy validation to model-based design controls, automated test management, and continuous compliance frameworks that support regulatory submissions and ongoing device maintenance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is changing medical device V&V by accelerating test design, anomaly detection, requirements traceability, and evidence review. AI-enabled tools can help identify gaps between user needs, design inputs, risk controls, test cases, and verification outputs, reducing manual reconciliation errors in complex product development programs. In software validation, machine learning can support automated regression testing, defect classification, and pattern recognition across large test datasets.

However, AI also increases validation complexity. AI-enabled medical device software must be evaluated for intended use, clinical relevance, dataset quality, bias, robustness, cybersecurity, and performance drift. Regulatory bodies increasingly expect transparent change control, documented training and test data governance, and lifecycle monitoring. The FDA's framework for predetermined change control plans for AI-enabled device software functions, the IMDRF principles for software as a medical device, and emerging international work on AI risk management are pushing manufacturers toward continuous V&V models that combine premarket evidence with postmarket performance controls.

Key Regional Insights: Asia-Pacific, North America, Europe & Emerging Markets

Asia-Pacific is becoming a major V&V growth engine as China, Japan, South Korea, India, Australia, and ASEAN markets expand local manufacturing, digital health adoption, and regulatory modernization. China's NMPA requirements, Japan's PMDA review expectations, India's medical device rule expansion, and Australia's TGA frameworks are encouraging manufacturers to localize compliance evidence while maintaining global technical files. Across Asia-Pacific, demand is increasingly shaped by software-enabled devices, local type testing, clinical evidence requirements, and the need to align domestic submissions with internationally recognized standards.

North America remains a benchmark region because FDA and Health Canada expectations strongly influence global V&V planning, particularly for software, cybersecurity, quality systems, human factors, and clinical evidence. Europe continues to emphasize rigorous technical documentation under MDR and IVDR, creating sustained demand for gap assessments, clinical evaluation support, performance evaluation evidence, and notified body-ready validation packages. Latin America, led by Brazil and Mexico, is prioritizing regulatory harmonization and local registration efficiency, while the Middle East and Africa are building stronger medical device oversight as healthcare infrastructure investment expands and procurement systems place greater weight on certified quality, safety, and performance evidence.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7 & NATO

ASEAN markets are strengthening device oversight while promoting regional access, making harmonized V&V documentation valuable for manufacturers seeking multi-country approvals through aligned technical, safety, and performance evidence. GCC countries are aligning healthcare modernization with stricter procurement and regulatory expectations, increasing the need for safety, performance, cybersecurity, and quality evidence that supports hospital purchasing decisions and national health system modernization.

The European Union is the most influential group for MDR and IVDR compliance, requiring robust clinical, technical, postmarket surveillance, and vigilance documentation. BRICS economies are important for scale, local manufacturing, and cost-sensitive innovation, but they require careful navigation of country-specific testing, registration, labeling, and postmarket obligations. G7 countries continue to set expectations for advanced medical devices, cybersecurity, software assurance, and AI governance, while NATO-aligned procurement environments place additional emphasis on supply chain resilience, cybersecurity assurance, trusted quality systems, and continuity of supply for connected healthcare technologies.

Key Country Insights for Global Medical Device V&V Strategy

The United States is central to global V&V strategy due to FDA design controls, software guidance, cybersecurity expectations, human factors requirements, and the transition to QMSR. Canada emphasizes risk-based licensing and quality system evidence, while Mexico and Brazil are important Latin American access points with growing regulatory sophistication and increasing reliance on structured technical documentation. In Europe, the United Kingdom, Germany, France, Italy, and Spain remain critical markets where MDR-aligned evidence, clinical evaluation, usability, postmarket surveillance, and vigilance drive V&V priorities; Russia requires localized regulatory planning under separate national rules and distinct conformity assessment expectations.

China, India, Japan, Australia, and South Korea shape Asia-Pacific demand through a mix of rapid innovation and distinct regulatory pathways. China prioritizes NMPA evidence and local testing expectations, India is expanding medical device regulation and domestic manufacturing under a broader policy focus on quality and access, Japan applies PMDA rigor to safety, clinical performance, and manufacturing controls, Australia relies on TGA conformity assessment principles and recognized international evidence, and South Korea is known for advanced digital health adoption and regulatory focus on software-enabled devices. Together with the United States, Canada, Mexico, Brazil, the United Kingdom, Germany, France, Russia, Italy, Spain, Japan, Australia, and South Korea, these countries define the practical evidence requirements that manufacturers must address when designing globally scalable V&V strategies.

Actionable Recommendations for Industry Leaders

Industry leaders should adopt a risk-based V&V operating model that begins at user needs and continues through postmarket performance monitoring. The highest-impact move is to connect requirements management, hazard analysis, design verification, validation protocols, software testing, usability evidence, cybersecurity controls, supplier qualification, and production process validation in a single traceable system.

Companies should invest in automated test management, digital quality management systems, and standardized protocol libraries aligned with ISO 13485, ISO 14971, IEC 62304, IEC 62366-1, IEC 60601, ISO 10993, and applicable regional regulations. For AI-enabled and connected devices, leaders should establish data governance, model change control, penetration testing, secure update validation, bias assessment, and real-world performance monitoring before submission. Early engagement with regulators, notified bodies, and independent test laboratories can reduce rework, strengthen technical files, and improve approval readiness.

Research Methodology

This executive analysis is built on a structured secondary research methodology using publicly available regulatory, standards, and industry sources. Core references include FDA medical device quality and software guidance, EU MDR and IVDR requirements, IMDRF software principles, ISO and IEC standards relevant to device V&V, and national regulatory frameworks from authorities such as Health Canada, TGA, PMDA, NMPA, and other recognized agencies.

Insights were synthesized through regulatory mapping, standards alignment, regional policy review, technology trend analysis, and cross-comparison of device development requirements across major markets. The methodology prioritizes verifiable information, current regulatory direction, and practical implications for manufacturers, contract research organizations, testing laboratories, quality leaders, and regulatory affairs teams, while excluding market sizing, market share, and forecasting assumptions.

Conclusion

Medical device validation and verification is evolving into a continuous, data-driven discipline that determines market access, product reliability, and patient safety. The combination of stricter quality requirements, MDR and IVDR obligations, software-led innovation, cybersecurity risk, and AI-enabled functionality is raising expectations for evidence quality across the device lifecycle.

Organizations that treat V&V as an integrated strategic capability will be better positioned to shorten development cycles, withstand regulatory audits, and scale globally. Success will depend on traceability, risk-based testing, digital validation tools, regional regulatory intelligence, and continuous postmarket learning that keeps devices safe, effective, secure, and compliant.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Medical Device Validation & Verification Market, by Services

• 7.1. Validation Services
  • 7.1.1. Design Validation
  • 7.1.2. Process Validation
  • 7.1.3. Software Validation
• 7.2. Verification Services
  • 7.2.1. Labeling & Packaging
  • 7.2.2. Material Verification
  • 7.2.3. Performance Testing

8. Medical Device Validation & Verification Market, by Device Class

• 8.1. Class I
• 8.2. Class II
• 8.3. Class III

9. Medical Device Validation & Verification Market, by Device Type

• 9.1. Imaging Systems
  • 9.1.1. CT Scanners
  • 9.1.2. MRI Systems
  • 9.1.3. Ultrasound Systems
    • 9.1.3.1. 2D Ultrasound
    • 9.1.3.2. 3D/4D Ultrasound
  • 9.1.4. X-Ray Systems
• 9.2. In Vitro Diagnostics
  • 9.2.1. Blood Glucose Monitors
  • 9.2.2. Immunoassay Analyzers
  • 9.2.3. Molecular Diagnostics
• 9.3. Monitoring Devices
  • 9.3.1. Blood Pressure Monitors
  • 9.3.2. ECG Monitors
  • 9.3.3. Fetal Monitors
  • 9.3.4. Pulse Oximeters
• 9.4. Surgical Instruments
  • 9.4.1. General Surgery Instruments
  • 9.4.2. Laparoscopic Instruments
  • 9.4.3. Orthopedic Instruments
• 9.5. Therapeutic Devices
  • 9.5.1. Defibrillators
  • 9.5.2. Dialysis Machines
  • 9.5.3. Infusion Pumps
  • 9.5.4. Ventilators

10. Medical Device Validation & Verification Market, by Application

• 10.1. Cardiology
• 10.2. Neurology
• 10.3. Oncology
• 10.4. Orthopedics
• 10.5. Respiratory

11. Medical Device Validation & Verification Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Contract Research Organizations
• 11.3. Diagnostic Laboratories
• 11.4. Hospitals

12. Medical Device Validation & Verification Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Medical Device Validation & Verification Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Medical Device Validation & Verification Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. ALS Limited
• 16.2. Applus Services SA
• 16.3. ATIC (Guangzhou) Co., Ltd.
• 16.4. Bureau Veritas SA
• 16.5. Charles River Laboratories International, Inc.
• 16.6. CSA Group Testing & Certification Inc.
• 16.7. Dekra SE
• 16.8. DNV AS
• 16.9. Element Materials Technology Group Limited
• 16.10. Eurofins Scientific SE
• 16.11. IFS Aktiebolag
• 16.12. Intertek Group PLC
• 16.13. Kiwa NV
• 16.14. LabWare, Inc.
• 16.15. Medistri SA
• 16.16. NSF International
• 16.17. QuEST Global Services Pte. Ltd.
• 16.18. Riverside Company
• 16.19. SGS SA
• 16.20. Steris Laboratories
• 16.21. TUV Nord AG
• 16.22. TUV Rheinland Group
• 16.23. TUV SUD
• 16.24. UL LLC